Spectral Platforms provides rapid diagnostic solutions in clinical microbiology. Its proprietary technology detects bacterial pathogens by measuring redox state changes, enabling faster pathogen identification and antimicrobial susceptibility testing.
Spectral Platforms is a biotechnology company focused on developing rapid diagnostic solutions for clinical microbiology. The company has created proprietary technology that detects bacterial pathogens by measuring metabolic markers and redox state changes in clinical samples. This approach aims to bypass traditional, time-consuming culture methods, offering diagnostic results for bacteria presence within 30 minutes. By enabling faster identification and antimicrobial susceptibility testing (AST), the platform is designed to provide actionable data for clinicians to initiate effective antibiotic therapy significantly earlier than current standards allow.
This technology is primarily intended for use in triaging patients at risk of sepsis and managing infectious diseases. By providing rapid and reliable results, including AST results for both single and poly-microbial samples, the company seeks to improve patient outcomes and optimize clinical decision-making. Founded in 2010 and based in Duarte, California, Spectral Platforms engages in research and development for the medical diagnostics industry, often working within the healthcare, biotechnology, and life sciences sectors to validate its diagnostic innovations for clinical environments.